NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scientific Officer; and Vignesh Rajah, Chief Medical Officer.